We first characterized GBM tumors after short-term treatment wherein anti-PD-L1 was incorporated into the therapeutic regimen on the same day as IM + anti-VEGF, when PD-L1 is expressed at low levels (Figure 7A). Here, CD274 is linked to glioblastoma.